STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer

Ilaria Attili, Niki Karachaliou, Laura Bonanno, Jordi Berenguer, Jillian Bracht, Jordi Codony-Servat, Carles Codony-Servat, Masaoki Ito, Rafael Rosell

Research output: Contribution to journalArticlepeer-review

Abstract

Immune checkpoint blockade has modified the treatment landscape for many types of tumors, including lung cancer. Still our knowledge on the biology of the interaction between tumor cells and the microenvironment is limited, preventing the optimal use of these new compounds and the maximum benefit that the patients can derive from them. We have actively worked on the role of STAT3, a transcriptional factor that causes innate resistance to targeted therapies in oncogene-addicted tumors. In this short review we take the opportunity to express our opinion and review existing knowledge on the immune role of STAT3 and the possible implications that this may have for the discovery of new biomarkers to predict response to immunotherapy, as well as new partners to combine with and increase the efficacy of immune checkpoint inhibitors.

Original languageEnglish
Pages (from-to)1758835918763744
JournalTherapeutic Advances in Medical Oncology
Volume10
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this